
|Videos|June 20, 2017
Phase II Results for Pembrolizumab Monotherapy in Metastatic TNBC
Author(s)Sylvia Adams, MD
Sylvia Adams, MD, associate professor, Department of Medicine, NYU Langone Medical Center, discusses phase II results from cohort A of the KEYNOTE-086 trial, which explored pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































